NASDAQ
HARP

Harpoon Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Harpoon Therapeutics Inc Stock Price

Vitals

Today's Low:
$6.81
Today's High:
$7.4951
Open Price:
$7.37
52W Low:
$5.44
52W High:
$17.13
Prev. Close:
$7.41
Volume:
35631

Company Statistics

Market Cap.:
$346.54 million
Book Value:
0.079
Revenue TTM:
$46.51 million
Operating Margin TTM:
-79.86%
Gross Profit TTM:
$-49478000
Profit Margin:
-86.72%
Return on Assets TTM:
-26.97%
Return on Equity TTM:
-272.17%

Company Profile

Harpoon Therapeutics Inc had its IPO on 2019-02-08 under the ticker symbol HARP.

The company operates in the Healthcare sector and Biotechnology industry. Harpoon Therapeutics Inc has a staff strength of 46 employees.

Stock update

Shares of Harpoon Therapeutics Inc opened at $7.37 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.81 - $7.5, and closed at $6.81.

This is a -8.1% slip from the previous day's closing price.

A total volume of 35,631 shares were traded at the close of the day’s session.

In the last one week, shares of Harpoon Therapeutics Inc have slipped by -23.83%.

Harpoon Therapeutics Inc's Key Ratios

Harpoon Therapeutics Inc has a market cap of $346.54 million, indicating a price to book ratio of 1.4933 and a price to sales ratio of 0.7455.

In the last 12-months Harpoon Therapeutics Inc’s revenue was $46.51 million with a gross profit of $-49478000 and an EBITDA of $-34907000. The EBITDA ratio measures Harpoon Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Harpoon Therapeutics Inc’s operating margin was -79.86% while its return on assets stood at -26.97% with a return of equity of -272.17%.

In Q2, Harpoon Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 143.5%.

Harpoon Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-9.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Harpoon Therapeutics Inc’s profitability.

Harpoon Therapeutics Inc stock is trading at a EV to sales ratio of 0.5868 and a EV to EBITDA ratio of 0.4334. Its price to sales ratio in the trailing 12-months stood at 0.7455.

Harpoon Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$63.20 million
Total Liabilities
$25.33 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Harpoon Therapeutics Inc ended 2024 with $63.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $63.20 million while shareholder equity stood at $3.00 million.

Harpoon Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $25.33 million in other current liabilities, 4000.00 in common stock, $-362801000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.80 million and cash and short-term investments were $45.56 million. The company’s total short-term debt was $2,875,000 while long-term debt stood at $0.

Harpoon Therapeutics Inc’s total current assets stands at $49.07 million while long-term investments were $0 and short-term investments were $12.76 million. Its net receivables were $0 compared to accounts payable of $3.63 million and inventory worth $0.

In 2024, Harpoon Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Harpoon Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$6.81
52-Week High
$17.13
52-Week Low
$5.44
Analyst Target Price
$5.33

Harpoon Therapeutics Inc stock is currently trading at $6.81 per share. It touched a 52-week high of $17.13 and a 52-week low of $17.13. Analysts tracking the stock have a 12-month average target price of $5.33.

Its 50-day moving average was $8.15 and 200-day moving average was $7.76 The short ratio stood at 0.65 indicating a short percent outstanding of 0%.

Around 953.8% of the company’s stock are held by insiders while 5222.4% are held by institutions.

Frequently Asked Questions About Harpoon Therapeutics Inc

The stock symbol (also called stock or share ticker) of Harpoon Therapeutics Inc is HARP

The IPO of Harpoon Therapeutics Inc took place on 2019-02-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$919.8
-62.35
-6.35%
$11.17
0.02
+0.18%
$2.85
0.05
+1.79%
$53.69
-4.24
-7.32%
$13.27
0.25
+1.92%
$12.46
-0.12
-0.95%
ESCORTS FINANCE LTD. (ESCORTSFIN)
$7.12
0.33
+4.86%
$34.4
-1.7
-4.71%
$10.45
0.03
+0.29%
$0.04
0
+5.25%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Address

131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080